

**Lung Cancer SPORE Workshop**  
**Meeting Agenda**  
**June 13-14, 2019**

7:45 AM      Opening Remarks      *Peter Ujhazy*

**Thursday, June 13, 2019**  
**New SPORES**  
**Moderator: Peter Ujhazy**

8:00 AM      FHCRC New Lung Cancer SPORE      *McGarry Houghton*  
8:20 AM      Emory New Lung Cancer SPORE      *Taofeek Owonikoko*

**Session 1 - KRAS, LKB1, and Related Pathways**  
**Moderator: Ferdinandos Skoulidis, MDACC**

8:40 AM      LKB1 Deficiency and KEAP1/NRF2 Pathway Alterations as Biomarkers of Response for ATR and ATM Inhibitors and Other Inhibitors of DNA Damage Response (DDR) in NSCLC      *Ana Galan-Cobo*

8:55 AM      Lactate Transporter Blockade as a Strategy to Overcome VEGF Inhibitor-Resistance in LKB1-deficient NSCLC      *Irene Guijarro*

9:10 AM      MDM2 Inhibition Combined with MEK Inhibition Induces Tumor Regression and Growth Inhibition in Non-Small Cell Lung Cancer (NSCLC) Patient Derived Xenografts (PDXs) with Wild Type TP53 and Mutant KRAS      *Bingliang Fang*

9:25 AM      STK11/LKB1 Genomic Alterations Are Associated with Lack of Benefit from Addition of Pembrolizumab to Platinum Doublet Chemotherapy in Non-Squamous Non-Small Cell Lung Cancer      *Ferdinandos Skoulidis*

9:40 AM      Development of Multi-Cell Type Organoid Cultures for Preclinical Studies of Immunotherapeutics for Lung Cancer      *Josiah Flaming*

9:55 AM      Epithelial Progenitor Dysfunction Sets the Stage for Squamous Cell Lung Cancer      *York Miller*

10:10 AM      Depletion of Myeloid-derived Suppressor Cells (MDSCs) Overcomes Anti-PD-1 Resistance in a Murine Model of LKB1-deficient Non Small Cell Lung Cancer (NSCLC)      *Rui Li*

10:25 AM      **Panel Discussion**

10:35 AM      *Break*

**Session 2 - Immunotherapy**  
**Moderator: Kathryn O'Donnell**

10:55 AM      Efficacy of Novel Immunogene-Combinations for Kras and LKB1 Mutant NSCLC in a Humanized Mouse Model      *Ismail M Meraz*

11:10 AM      In situ Vaccination with CCL21-modified Dendritic Cells (CCL21-DC) Combined with Checkpoint Blockade in Murine Models of NSCLC      *Raymond John Lim*

11:25 AM      The Integrated Stress Response Pathway Controls PD-L1 Translation in Lung Cancer      *Kathryn O'Donnell*

11:40 AM      Phase 1/1b Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer      *James Saller*

**Lung Cancer SPORE Workshop  
Meeting Agenda  
June 13-14, 2019**

11:55 AM      Variation in the Assessment of Immune-related Adverse Event Occurrence, Type, Grade, and Timing      *David Gerber*

12:10 PM      Systemic Immune Dysfunction in Cancer Patients Driven by IL6 and IL8 Induction of an Inhibitory Receptor Module      *Tullia Bruno*

12:25 PM      **Panel Discussion**

12:35 PM      *Lunch on Your Own*

1:45 PM      Putting the Patient Perspective into Translational Research      *Kim Norris*

**Session 3 - EGFR and Other Signaling Pathways  
Moderator: Jacquelyne Robichaux**

2:15 PM      Analysis of the Sensitivity of EGFR and HER2 Exon 20 Mutations Identifies Poziotinib as a Potent and Selective Inhibitor of Exon 20 Mutations and An Enhancer of T-DM1      *Jacquelyne Robichaux*

2:45 PM      EGFR Mutations Promote Hypoxia-Independent Upregulation of HIF-1 $\alpha$  and VEGF and a VEGF-dependent Phenotype      *John Heymach*

2:30 PM      T790M-independent EGFR TKI Resistance is Associated with a Broad Multi-Drug Resistant Phenotype but Selective Vulnerabilities to Spindle Assembly Complex (SAC) and CDK Inhibitors      *Monique Nilsson*

3:00 PM      **Panel Discussion**

3:10 PM      *Break*

**Session 4 - Therapeutic Resistance  
Moderator: Katerina Politi**

3:40 PM      Adaptive Mechanisms of Resistance to Targeted Therapy in EGFR Mutant Brain Metastasis      *Sally Adua*

3:55 PM      BRG1 as a Mediator of Resistance to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma      *Fernando de Miguel*

4:10 PM      Resistance to Targeted Therapies as a Gradual Adaptation to Inhibitor Specific Selective Pressures      *Andriy Marusyk*

4:25 PM      Combinatorial Therapeutic Approaches to Treat NRF2/KEAP1 Mutant NSCLC      *Laura Torrente*

4:40 PM      **Panel Discussion**

4:50 PM      *Adjourn*

**Lung Cancer SPORE Workshop**  
**Meeting Agenda**  
**June 13-14, 2019**

Dinner Session @ Hilton Rockville  
 How It All Started: Reminiscing the Beginning of Lung Cancer SPOREs  
 John Minna, Jack Roth, Paul Bunn, York Miller  
 6:30 PM - Dinner is Served  
 7:15 PM - Dinner Program

**Friday, June 14, 2019**

**Keynote Speaker: Lieping Chen**  
**8:00am**  
**A Systematic Approach to Unfold Lung Cancer Resistance to Immunotherapy**

**Session 5 - Premalignancy, Risk Stratification, and Chemoprevention**  
**Moderator: Steve Dubinett**

- 8:45 AM      HLA Affinity for Peptides Derived from Mutant EGFR Identifies a Group of Patients with Favorable Prognosis      *Anastasios Dimou*
- 9:00 AM      A Combined Imaging, Blood, and Clinical Biomarker Strategy for Lung Cancer Risk Reclassification in Patients with Indeterminate Pulmonary Nodules      *Michael Kammer*
- 9:15 AM      A Human Bronchial Epithelial Cell Model Demonstrates a Role for Glutamine Metabolism in DNA Damage and Oncogenic Transformation      *Pierre Massion*
- 9:30 AM      SGLT2 is a Diagnostic and Therapeutic Target for Early Stage Lung Adenocarcinoma      *Claudio Scafoglio*
- 9:45 AM      The Genomic Landscape and Immune Contexture of Lung Adenomatous Premalignancy      *Linh Tran*
- 10:00 AM      **Panel Discussion**
- 10:10 AM      *Break*

**Session 6 - Novel Targets**  
**Moderator: Jerry Shay**

- 10:30 AM      Therapeutic Targeting of Telomeres Induces Replication Stress Vulnerabilities in Lung Cancer      *Jerry Shay*
- 10:45 AM      Inhibition of RUVBL1/2 Causes Replication Catastrophe and Synergizes with Ionizing Radiation in Non-Small Cell Lung Cancer      *Paul Yenerall*
- 11:00 AM      Panel Discussion

**Session 7 - Molecular Profiling and Biomarkers**  
**Moderator: Rex Yung**

- 11:10 AM      Identifying Metabolic Programs in Human Lung Cancer That Indicate Tumor Aggressiveness      *Brandon Faubert*

**Lung Cancer SPORE Workshop  
Meeting Agenda  
June 13-14, 2019**

11:25 AM	Lung Cancer Prognosis Modeling Via Integrating Omics and Histopathological Imaging Data	<i><b>Shuangge Ma</b></i>
11:40 AM	In vivo Imaging of Mitochondrial Membrane Potential in Non-Small Cell Lung Cancer	<i><b>Milica Momcilovic</b></i>
11:55 AM	Increased Frequency of Bystander T cells in the Lungs is Associated with Recurrence in NSCLC	<i><b>Alexandre Reuben</b></i>
12:10 PM	ISH Chromogenic Staining of Non-coding Nascent RNA for Detection of Lung Cancer Imprinting Genes	<i><b>Rex Yung</b></i>
12:25 PM	Panel Discussion	

12:35 PM ***Break***

**Session 8 - Small Cell Lung Cancer  
Moderator: Anish Thomas**

1:45 PM	Targeting Jumonji Proteins for Therapeutic in SCLC	<i><b>Aiden Nguyen</b></i>
2:00 PM	Drug Combinations in SCLC Complex Spheroids in Culture	<i><b>Beverly Teicher</b></i>
2:15 PM	Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never-smokers	<i><b>Anish Thomas</b></i>
2:30 PM	Quantitative Proteomic Analysis Identifies IGFBP5 as a Secreted Marker for ASCL1High Pulmonary Neuroendocrine Tumors	<i><b>Xu-Dong Wang</b></i>
2:45 PM	Panel Discussion	

**Session 9 - Premalignancy, Risk Stratification, and Chemoprevention  
Moderator: Wei Wei**

2:55 PM	Use and Perceptions of Electronic Nicotine Delivery Systems Among Patients Attending Lung Cancer Screening	<i><b>Krysten Bold</b></i>
3:10 PM	Computational Staining of Pathology Images to Study Tumor Microenvironment in Lung Cancer	<i><b>Shidan Wang</b></i>
3:25 PM	Tumor-growth Modeling for Informed Go/No-go Decisions	<i><b>Wei Wei</b></i>
3:40 PM	Panel Discussion	

3:50 PM ***Adjournment***